PATENT CLAIM ANALYSIS

Application Number: 16027029
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["548", "400000"]

Abstract:
Provided herein are Mcl-1 antagonist compositions and methods of treating cancer using the compositions described herein.

Claim (Index 102):
The method of  claim 101 , wherein:\n R 6  is R 16 -substituted or unsubstituted C 1-3  alkyl, R 16 -substituted or unsubstituted C 1 -C 3  heteroalkyl, R 16 -substituted or unsubstituted C 5 -C 6  aryl, or R 16 -substituted or unsubstituted cyclopentadienyl; and R 16  is \u2014O, \u2014OH, \u2014NH 2 , substituted or unsubstituted 6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or unsubstituted pyridinyl.

Metadata:
- Claim Count in Document: 245.0
- Percentile: 95.0
- Lexical Diversity: 1.13333
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15123232', '15662861', '15700040', '15214282', '15421258']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8179440920927721
- 35 USC 102 Novelty (BERT): 0.6677187907896712
- Combined Prediction Score: 0.802921561962462
- Mean Citation Score: 615.5831919999998
- Max Citation Score: 733.3489
- Similarity Product: 616.0776179151654

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test